TENSIVE SRL

Tensive is a Milan-based, clinical-stage medical device company developing bioresorbable scaffold technologies for breast reconstruction and tissue marking. Its REGENERA™ and SOFTAG™ scaffolds are designed to provide volume while supporting the growth of new tissue, with the aim of enabling natural breast restoration and improving quality of life for patients. The technologies are being developed for breast reconstruction after lumpectomy and for tissue marking following breast-conserving surgery.

Tensive reports that a first-in-human study in benign tumor resections demonstrated safety and encouraging clinical outcomes. A pivotal trial involving 94 breast cancer patients is ongoing, with the company reporting encouraging performance measures and high patient and surgeon satisfaction. The products remain under development and are not commercially available; Tensive says first approvals are expected in early 2027.

The company advances its work through research, clinical studies and scientific collaboration. It also maintains a pipeline of medical device programs and has issued and pending patents. Tensive is supported by investors and shares clinical and company updates through publications, press releases and industry events.